Medexus Pharmaceuticals Inc. (MEDXF)
OTCMKTS · Delayed Price · Currency is USD
2.020
+0.030 (1.50%)
At close: Dec 26, 2025
Medexus Pharmaceuticals Revenue
Medexus Pharmaceuticals had revenue of $24.74M in the quarter ending September 30, 2025, a decrease of -5.94%. This brings the company's revenue in the last twelve months to $104.10M, down -0.63% year-over-year. In the fiscal year ending March 31, 2025, Medexus Pharmaceuticals had annual revenue of $108.33M, down -4.18%.
Revenue (ttm)
104.10M
Revenue Growth
-0.63%
P/S Ratio
0.63
Revenue / Employee
1.14M
Employees
91
Market Cap
65.71M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 108.33M | -4.72M | -4.18% |
| Mar 31, 2024 | 113.05M | 4.96M | 4.59% |
| Mar 31, 2023 | 108.10M | 31.40M | 40.93% |
| Mar 31, 2022 | 76.70M | -2.96M | -3.71% |
| Mar 31, 2021 | 79.66M | 24.15M | 43.52% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| American Oncology Network | 1.76B |
| Veradigm | 588.02M |
| Glass House Brands | 196.17M |
| Global Cord Blood | 196.10M |
| Elite Pharmaceuticals | 122.89M |
| Silence Therapeutics | 25.83M |
| OpGen | 9.00M |
| Northwest Biotherapeutics | 937.00K |
Medexus Pharmaceuticals News
- 5 weeks ago - Medexus Announces Normal Course Issuer Bid, or NCIB, for Its Common Shares - Newsfile Corp
- 5 weeks ago - Medexus Announces US$51.0 million in New Credit Facilities and Intention to Commence Normal Course Issuer Bid, or NCIB, for its Common Shares - Newsfile Corp
- 6 weeks ago - Medexus Pharmaceuticals Inc. (MDP:CA) Q2 2026 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Medexus Announces Fiscal Q2 2026 Results, Driven by Strong Year-To-Date Product-Level Performance of GRAFAPEX (treosulfan) for Injection - Newsfile Corp
- 7 weeks ago - Medexus Schedules Second Fiscal Quarter 2026 Conference Call - Newsfile Corp
- 3 months ago - Medexus Holds Annual Meeting of Shareholders and Announces Election of Directors - Newsfile Corp
- 3 months ago - Medexus Pharmaceuticals Inc. (MDP:CA) Shareholder/Analyst Call Prepared Remarks Transcript - Seeking Alpha
- 4 months ago - Medexus Pharmaceuticals Inc. (MEDXF) Q1 2026 Earnings Call Transcript - Seeking Alpha